Home |  Map |  Imprint
Search:	Company|Portfolio|Investment Criteria|Contact Portfolio Press Life Sciences 24. August 2006 TopoTarget and CuraGen announce Southwest Oncology Group opens new lymphoma trial with PXD101 18. August 2006 Epigenomics announces change in the Executive Board 10. August 2006 TopoTarget and CuraGen Initiate Clinical Program Evaluating Oral Administration of PXD101 - Phase I trial to establish the dose and frequency for oral PXD101 in patients with advanced solid tumors - 7. August 2006 Epigenomics AG Enters into Agreement with Johnson &Johnson Pharmaceutical Researach &Development, L.L.C 27. July 2006 US Patent Granted for 4SC’s Clinical Project 21. July 2006 Epigenomics AG Decides Capital Increase − Affymetrix Signs For New Shares 17. July 2006 KeyNeurotek AG Strengthens Finance and Clinical Development Management 14. July 2006 TopoTarget and CuraGen Announce Initiation of Phase I/II Trial of PXD101 for Hepatocellular Cancer 5. July 2006 Epigenomics AG Presents New Clinical Data on Colorectal Cancer Screening Markers 4. July 2006 DeveloGen receives Grant for DiaPep277® Program 29. June 2006 Ardana appoints new non-executive to the board 28. June 2006 4SC announces further research collaboration with Solvay 27. June 2006 Epigenomics AG and Affymetrix announce Strategic Diagnostics Platform Agreement 26. June 2006 Epigenomics AG and Wellcome Trust Sanger Institute Release Epigenetic Data on the first 3 Chromosomes 21. June 2006 DeveloGen AG: DiaPep277® mechanism of action demonstrated 15. June 2006 Probiodrug Closes a EUR 10.6 Million (US$ 13.4 million) Series C Financing Round 13. June 2006 DeveloGen AG und ihr Vorstandsvorsitzender Dr. Günther Karmann trennen sich in gegenseitigem Einvernehmen; Dr. Cord Dohrmann, Chief Scientific Officer, in den Vorstand berufen 8. June 2006 Epigenomics AG announces Research Collaboration with Stanford University 24. May 2006 elbion AG Increases Series A Financing to €35 Million 16. May 2006 Epigenomics AG Announces Continuation of Pharmaceutical Biomarker Research Collaboration with AstraZeneca in the Field of Oncology 15. May 2006 4SC reports results of first quarter 12. May 2006 Epigenomics Receives Award for Best Oral Presentation at MipTec 2006 11. May 2006 4SC completes capital increase 3. May 2006 Epigenomics AG Reports First Quarter 2006 Results 3. May 2006 Ardana announces block lisiting 25. April 2006 Qiagen Eliminates Key Bottleneck in Epigenetic Research 24. April 2006 Designed for easy operation: Xenon - Klotz Digital's latest all-in-one mixer revealed at NAB 2006 12. April 2006 Ardana announces positive phase II results for testosterone cream 12. April 2006 4SC compound active against influenza viruses 5. April 2006 Clinical Study Proves Prognostic Power of Epigenomics' Biomarker in Prostate Cancer 3. April 2006 Epigenomics Presents Data Confirming Screening for Methylated DNA in Blood as Key to Early Colorectal Cancer Detection 30. March 2006 4SC AG reports financial results for financial year 2005 24. March 2006 Epigenomics AG Reports Financial Results for Fiscal Year 2005 22. March 2006 Epigenomics AG Reports Extension of Blood Screening Product Collaboration 17. March 2006 Ardana appoints Klaus Falk as VP Sales & Marketing 15. March 2006 Avontec GmbH starts new research laboratory at Heidelberg University Groundbreaking research into transcription factor technology continues – target indications include severe asthma and inflammatory skin diseases 10. March 2006 Epigenomics Confirms Lead Marker for Prediction of Breast Cancer Relapse 28. February 2006 GPC Biotech to Present at Two Upcoming Conferences in the U.S. 27. February 2006 GPC Biotech Presents New Satraplatin Clinical Data from Pharmacokinetics Study at ASCO Prostate Cancer Symposium New preclinical data on efficacy of satraplatin in prostate cancer cells and with Taxotere® also presented 24. February 2006 GPC Biotech Raises € 36.2 Million in Private Placement with SAP Co-Founder Dietmar Hopp 14. February 2006 BioWa and Aphton Announce Licensing of BioWa’s POTELLIGENT™ Technology Aphton to Use BioWa’s POTELLIGENTTM Antibody Technology for Development of Preclinical IGN312 Anti-Lewis Y antibody 14. February 2006 BioWa and Aphton Announce Licensing of BioWa’s POTELLIGENT™ Technology Aphton to Use BioWa’s POTELLIGENTTM Antibody Technology for Development of Preclinical IGN312 Anti-Lewis Y antibody 14. February 2006 European Regulatory Committee Recommends Orphan Drug Status for GPC Biotech’s Anticancer Monoclonal Antibody 1D09C3 for Multiple Myeloma 7. February 2006 Aphton to expand licensing and commercialization agreement into Europe for IGN311 31. January 2006 DeveloGen receives JDRF Grant for Beta-Cell Regeneration Program 31. January 2006 Ardana's novel testosterone cream remains on track for Q4 2007 launch following Pre-Ind Meeting with US FDA Company completes Phase II dose-finding study enrolment 30. January 2006 Epigenomics AG Pursuing Development of Tamoxifen Response Test 27. January 2006 GPC Biotech AG: Orphan Drug Designation Granted by European Commission for Anticancer Monoclonal Antibody 1D09C3 for Chronic Lymphocytic Leukemia 17. January 2006 4SC enters next phase of drug discovery collaboration with Sanwa Kagaku Kenkyusho 11. January 2006 DeveloGen Announces Changes to Scientific Advisory Board 10. January 2006 elbion AG Completes € 25 Million Series A Financing 4. January 2006 Epigenomics Successfully Completes Biomarker Validation Study for Prostate Cancer Classification Test Product Forms Foundation of Company's Tissue-Based Product Pipeline 4. January 2006 Epigenomics AG adds Regulatory Affairs and Marketing Expertise to Senior Management 19. December 2005 Epigenomics DNA Methylation Test Successfully Detects Colorectal Cancer in Blood Clinical Studies Demonstrate Proof-of-Concept for Early Detection of Disease 15. December 2005 4SC AG: Share trading at the Frankfurt Stock Exchange 13. December 2005 Milestone and Licensing decision on tamoxifen response test postponed to end of January 2006 13. December 2005 Successful completion of financing round totalling € 7.75 million KeyNeurotek AG takes over Sirenade Pharmaceuticals AG 7. December 2005 Aphton Announces Receipt of NASDAQ Notice of Non-Compliance; Aphton to Appeal 30. November 2005 Pre-listing capital increase successfully completed / Application for stock exchange listing filed 25. November 2005 Aphton Corporation Announces Closing of Long-Term Debt Restructuring 17. November 2005 Aphton Announces Closing of Commercialization and Manufacturing Agreements for IGN311 with Celltrion 15. November 2005 Epigenomics AG announces end of VC pooling 15. November 2005 Aphton announces adoption of mandatory retirment policy for the board of directors 9. November 2005 Aphton announces mutual agreement to dissolve co-promotion and licensing agreemnet related to anticancer product INSEGIA™ with Sanofi Pasteur 9. November 2005 Ardana signs Agreement with PHARMACURO to market STRIANT™ SR in the nordic region 2. November 2005 Epigenomics AG reports third quarter 2005 financial results 31. October 2005 Epigenomics reports Tamoxifen treatment response test study results inconclusive 31. October 2005 Ardana announces positive Phase I results and starts Phase II trials for NOVEL testosterone cream 5. October 2005 Ardana announces german lounch of STRIANT™ SR through CYTOCHEMIA AG 5. October 2005 DeveloGen Announces End-of-Phase II Meeting with FDA, EMEA Scientific Advice Meeting and First-Patient-In for Phase III Clinical Trial of DiaPep277® 30. September 2005 Epigenomics and Roche Diagnostics extend R&D collaboration agreement Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, today announced an extension to its existing agreement with Roche Diagnostics, a world leader in molecular diagnostics. The R&D part of the collaboration, which covers the development of five cancer diagnostic tests, has been extended for a minimum of 6 months, with the option to prolong and potentially expand for another 18 months. Financial terms were not disclosed. 27. September 2005 TOPOTARGET AND CURAGEN INITIATE PHASE Ib CLINICAL TRIAL WITH PXD101 FOR ADVANCED COLORECTAL CANCER - Proof-of-concept trial evaluating PXD101 combination therapy with 5-fluorouracil for advanced solid tumours and colorectal cancer - 21. September 2005 Ardana accelerates anticipated launch of Teverelix Long Acting (LA) in benign prostatic hyperplasia following pre-ind meeting with the US FDA Ardana plc (LSE:ARA), the emerging pharmaceutical company focused on improving human reproductive health, today reports that the launch of its lead compound, the GnRH antagonist Teverelix Long Acting (LA) in benign prostatic hyperplasia (BPH), could be advanced by up to two years, following a pre-Investigational New Drug (IND) application meeting with the FDA at which consensus on the company’s development plan for the therapy was reached. It was previously expected that Teverelix in BPH could reach the market in 2012. 20. September 2005 Elbion AG appoints Dr. Thomas Taapken as Chief Financial Officer and Member of the Executive Board elbion AG, a Radebeul (Germany) based and privately held, biopharmaceutical company dedicated to the development of novel small molecule drugs in the areas of inflammation and CNS disorders, announced today that Dr. Thomas Taapken has been appointed Chief Financial Officer by the supervisory board of the company. 14. September 2005 DeveloGen Presents Positive Phase II Data at EASD Conference DeveloGen, a biopharmaceutical company focusing on novel treatments for metabolic disorders, today presented positive results of two phase II clinical trials of DiaPep277® for the treatment of type 1 diabetes at the 41st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Athens 12. September 2005 Epigenomics AG announces resignation of Aron Braun 7. September 2005 Clinical development of Ardana's Teverelix Long Acting (LA) in prostate cancer continues on track following pre-IND application meeting with the United States Food & Drug Administration (FDA) 30. August 2005 With the New Development candidate NSD-551 TopoTarget and Neurosearch expand their collaboration within cancer treatment 17. August 2005 4SC appoints new Chief Financial Officer and announces changes to Supervisory Board 16. August 2005 Debiopharm and DeveloGen Announce Partnering of Myasthenia Gravis Program 15. August 2005 Retiring Epigenomics executive Gary Schweikhardt released from lock-up at year-end 9. August 2005 TopoTarget receives $4.8 million milestone payment from Curagen Corp as ongoing Phase II trial of PXD101 is extended to the United States - Study evaluating PXD101 in multiple myeloma scheduled for completion mid 2006 - 4. August 2005 TopoTarget A/S - Capital increase as a result of emmployee warrant exercise 3. August 2005 Epigenomics AG report second quarter and first half 2005 financial results 2. August 2005 Epigenomics AG announces Gary Schweikhardt to retire 26. July 2005 Acquisition of GlycArt Biotechnology completed 19. July 2005 Roche acquires Swiss based GlycArt Biotechnology to strengthen expertise in therapeutic antibody research 12. July 2005 4SC receives financing trough new technology funds from KfW and Bayern Kapital 7. July 2005 US FDA grants TopoTarget Orphan Drug Designation (ODD) for PEAC® in patients with FAP, a genetic predisposition to colon cancer 28. June 2005 TopoTarget A/S – Full exercise of over-allotment option 28. June 2005 SAVENETM (dexrazoxane) demonstrates 97% success rate in Phase II/III trial to treat accidental extravasation of anthracycline anti-cancer agents - TopoTarget closes patient enrollment as requisite number of subjects is recruited - 17. June 2005 Ardana appoints New Non-Executive to The Board 16. June 2005 Ardana signs agreement with Cytochemia to market Striant™ SR in Germany 6. June 2005 Aphton announces appointment of Manfred Ruediger, Ph.D. to the position of Chief Operating Officer 1. June 2005 DeveloGen appoints New Scientific Advisory Board and announces changes in Senior Management Team 26. May 2005 Ardana announces successful results in a Phase II Study of Teverelix LA in Benign Prostatic Hyperplasia 24. May 2005 elbion AG increases Series A financing to € 35 million 23. May 2005 TopoTarget receives broad US and EU patents for key HDAC inhibitors Awards strengthen Company’s leading HDAC inhibitor drug development programme 17. May 2005 Epigenomics AG validates DNA methylation test as predictor of disease recurrence in breast cancer patients Data presented at ASCO and published in cancer research provides valuable information to guide treatment options 17. May 2005 TopoTarget and CuraGen present PXD101 Phase I results at ASCO Preliminary data suggests PXD101 is well tolerated following oral or intravenous administration 12. May 2005 Ardana announces successful results in second Phase II of Teverelix LA in prostate cancer 12. May 2005 TopoTarget and CuraGen announce co-operative R&D agreement with US National Cancer Institute for PXD101 10. May 2005 4SC receives BMBF grant for development of new drug candidates for treatment of multiple sclerosis 4. May 2005 Epigenomics AG reports first quarter 2005 results 2. May 2005 Epigenomics AG and QIAGEN enter into strategic collaboration in DNA Methylation Leading preanalytical solutions for methylation analysis to focus on in-vitro molecular diagnostics and pharmacogenomics markets 20. April 2005 New preclinical data on HDAC inhibitor PXD101 demonstrates down regulation of common mechanism of cancer therapy resistance - Results presented at the AACR 96th Annual Meeting - 20. April 2005 Epigenomics AG presents positive data at AACR Epigenomics AG presents positive prognostic biomarker data from studies in prostate and breast cancer at AACR 19. April 2005 Ardana announces positive results in Phase I study of oral Growth Hormone Secretagogue 5. April 2005 4SC and Schwarz Pharma agree on long-term research cooperation 24. March 2005 Apthon announces closing of Igeneon acquisition 24. March 2005 4SC successfully concludes Phase I study for product candidate for the treatment of autoimmune diseases 23. March 2005 GLYCART biotechnology appoints Andreas Emmenegger as Chief Financial Officer 23. March 2005 Epigenomics AG reports financial results for fiscal year 2004 16. March 2005 TopoTarget A/S raises Euro 15 million and attracts new investor - Series C funding will support clinical development until first product launches - 14. March 2005 Epigenomics AG to present data from breast cancer outcome prediction study 4. March 2005 Ardana announces successful completion of IPO 1. March 2005 TopoTarget A/S acquires G2M Cancer Drugs AG - Move creates strong oncology company with dominance in the field of HDAC inhibitors - 17. February 2005 Ardana announces successful results in Phase II trial of Teverelix in prostate cancer 15. February 2005 4SC and Sanwa Kagaku Kenkyusho enter into multi-year drug discovery collaboration 2. February 2005 Ardana signs three-year extension to its exclusive agreement with MRC Human Reproductive Sciences Unit - Deal gives Ardana first option on strategic research projects - 20. January 2005 Epigenomics AG announces end of IPO Lock Up period 21. December 2004 Epigenomics achives key milestone in development of prostate cancer classification test Company discovers biomarkers for prostate cancer aggressiveness 15. December 2004 Aphton Corporation to acquire igeneon extending its leadership position in cancer immunotherapy Acquisition represents pivotal step to establishing a broad oncology franchise 2. December 2004 Epigenomics AG and Roche Diagnostics expand R&D structure of collaboration 18. November 2004 Morphochem and Probiodrug collaborate in research and development of novel innovative dipeptidyl peptidase IV (DP IV) inhibitors for the treatment of Anxiety and Depression 9. November 2004 DeveloGen receives R&D Funds for diabetic Complications Project German Federal Ministry of Education and Research supports Research Project 8. November 2004 igeneon announces survival data of Phase II trial with IGN101 cancer vaccine Statistically significant survival prolongation in group of patients with metastatic rectal cancer 3. November 2004 Epigenomics AG reports third quarter 2004 results 2. November 2004 4SC achieves milestone in research collaboration with Sonofi-Aventis 28. October 2004 Ardana receives Special Biotechnology Award for second year running in Deloitte & Touche Fast 50 celebrations 28. October 2004 Ardana announces completion of European Mutual Recognition Process for StriantTM testosterone replacement therapy in men with primary of secondary hypogonadism 20. October 2004 igeneon names Guenter Schirmer, M.D., Ph.D., Medical Director 12. October 2004 Sirenade Pharmaceuticals announces breakthrough in the development of Tau-Directed therapeutics to treat Alzheimer’s Disease 7. October 2004 Epigenomics forms pharmacodiagnostic research collaboration with Biogen Idec in oncology 5. October 2004 aws to back igeneon cancer research program EUR 5 million loan guarantee for development of innovative cancer drugs 29. September 2004 Sirenade Pharmaceuticals appoints Lynn Butler as CEO and restructures management team 22. September 2004 GLYCART biotechnology to present at UBS 2004 Global Life Sciences Conference 21. September 2004 Roche and GLYCART to discover new therapeutic antibodies 21. September 2004 4SC AG and MUTABILIS S.A. collaborate in the field of infectious diseases 24. August 2004 Initial public offering of Epigenomics AG: end of stabilization period 16. August 2004 Closing of Probiodrug-Prosidion transaction and changes in management & board 12. August 2004 Epigenomics AG meets key milestone in breast cancer test development 2. August 2004 Ardana appoints Vice-President of Pre-Clinincal Sciences 16. July 2004 Epigenomics listing to occur Monday July 19, 2004 Epigenomics prices IPO on Frankfurt Stock Exchange at € 9.00 per share 7. July 2004 Solvay Pharmaceuticals selects Sirenade as protein structure service provider 6. July 2004 Probiodrug awarded a €1.9mio BioChancePlus grant to fund a drug-discovery program for the treatment of neurodegenerative disorders 29. June 2004 Ardana appoints two Non-Executive Directors to the Board 21. June 2004 Senetek licenses Invicorp® erectile dysfunction treatment to Ardana for Europe Ardana to assume full regulatory responsibility and Senetek to receive royalities and milestone payments 18. June 2004 Osi Pharmaceuticals’ Subsidary Prosidion Acquires Dipeptidyl Peptidase IV Platform From Probiodrug - Includes Phase II Development Candidate P93/01 - 17. June 2004 Manfred Ruediger appointed new CEO of igeneon Founder Hans Loibner to retire after 5 years at the helm 14. June 2004 Sirenade Pharmaceuticals AG initiates Phase I study with SRN-001 (DHEC) 8. June 2004 4SC AG announces grant of US patent for computer-aided screening method 7. June 2004 Epigenomics presents positive results from studies using DNA methylation markers for predicting disease recurrence in breast cancer patients 3. June 2004 Ardana strengthens senior management team Mr Simon Best appointed as Chairman, Dr Maureen Lindsay appointed as Chief Executive Officer and Mr Graham Lee appointed as Chief Financial Officer 3. June 2004 UK launch for Ardana's Striant SR testosterone replacement therapy for men with primary or secondary hypogonadism 28. May 2004 Ardana completes extension to Series B fundraising 17. May 2004 DeveloGen completes 19 million Euro financing round 12. May 2004 Update on Probiodrug's Patents 12. May 2004 AVONTEC appoints Chief Financial Officer and completes management team 10. May 2004 Sirenade Pharmaceuticals AG and Polichem S.A. sign an exclusive license agreement in CNS 4. May 2004 4SC AG and Serono sign worldwide agreement to develop and commercialize orally active compounds for the treatment of autoimmune disorders - Lead Compound SC12267 Completing Phase I Clinical Trials - 28. April 2004 SIRENADE Pharmaceuticals AG announces the appointment of Dr. Wolfgang Schuette as Chief Medical Officer 27. April 2004 Epigenomics and academic partners receive BMBF grant to develop novel techniques for early cancer detection based on DNA-methylation 25. April 2004 igeneon raises EUR 26.7 million in a Series C financing round co-led by Burrill & Company and 3i 30. March 2004 Joint forces against vitiligo - development co-operation agreement signed with Spirig Pharma for vitiligo product 23. February 2004 4SC AG spins off quattro research GmbH - a company which develops and markets software solutions for the life science industry 11. February 2004 AVONTEC appoints VP Product Development 20. January 2004 Epigenomics develops technique for sensitive early detection of cancer 13. January 2004 Epigenomics to enter collaboration with AstraZeneca Project to use paraffin samples for the identification of biomarkers 13. January 2004 NADAG and SiREEN announce merger to form SIRENADE Pharmaceuticals AG and launch €20 million financing round 7. January 2004 igeneon expands management board in 2004 Dr. Manfred Rüdiger new Chief Operating Officer 16. December 2003 Probiodrug´s meeting of the Scientific Advisory Board highlighted programs in metabolic and neuronal disorders 16. December 2003 Epigenomics and Wyeth to enter collaboration Project to identify drug response markers 15. December 2003 Probiodrug AG Reported on the Results of its Clinical Phase IIa Trial with the DPIV Inhibitor P93/01 in Type 2 Diabetes and its Patent Licensing Programs 10. December 2003 4SC AG starts phase I study of product candidate for treatment of rheumatoid arthritis 26. November 2003 GLYCART Biotechnology closes $13.6 million private financing round 20. November 2003 AVONTEC successfully completes phase I clinical trials for its first product candidate 17. November 2003 4SC appoints Patrick Schwarz-Schütte, Dr Brian Morgan and Dr Holger Reithinger to its supervisory board 14. November 2003 First Clinical Results in the Treatment of Psoriasis 13. November 2003 Peptor and DeveloGen announce intention to merge 11. November 2003 igeneon initiates further pivotal Phase III clinical trials with IGN101 cancer vaccine Controlled Phase III study in metastatic colorectal cancer First controlled Phase III study with a cancer vaccine in adjuvant breast cancer worldwide 30. October 2003 igeneon presents at "International Society for Biological Therapy of Cancer" (iSBTc) 18th Annual Meeting Lecture on disseminated tumor cells as surrogate marker in cancer therapy Presentation of latest clinical developments in its cancer immunotherapy product portfolio 20. October 2003 AVONTEC’s First Compound to Enter Clinical Development 20. October 2003 SWITCH Biotech appoints Stefan Schulze Chief Executive Officer 13. October 2003 SWITCH Biotech selects 4SC as partner for the discovery and development of active compounds for the treatment of Psoriasis 13. October 2003 SiREEN AG received a research grant for its innovative cancer research program from the Bavarian Ministry of Economics. 7. October 2003 Epigenomics and the Wellcome Trust Sanger Institute launch Human Epigenome Project to follow EU-pilot study 10. September 2003 DeveloGen and Evotec OAI announce a strategic drug discovery and development alliance for metabolic diseases 9. September 2003 AVONTEC Receives Key Patent in the US 5. September 2003 Probiodrug's DPIV inhibitor P93/01 for the treatment of type 2 diabetes in patients 3. September 2003 SiREEN AG and its academic collaboration groups are awarded with a research grant from the Bavarian Research Foundation 20. August 2003 Certification according to DIN EN ISO/ICE 17025:2000 22. July 2003 Roche expands the strength of its product franchise in Rheumatoid Arthritis and Transplantation Roche acquires Cardion’s promising IL-15 antagonist 15. July 2003 4SC and Esteve agree on broadening their research partnership 13. July 2003 igeneon presents at Late Breaking Poster Session at AACR (American Association for Cancer Research) meeting Monoclonal antibody IGN311 data show additional mechanism of action similar to Herceptin® and Erbitux® Co-expression of igeneon's targets correlates with poor prognosis in breast cancer 9. July 2003 EPIGENOMICS spins off start-up Epiontis DNA-methylation is applied in cell therapy and tissue engineering 25. June 2003 AVONTEC receives German Founders Award 3. June 2003 Avontec appoints new CEO 2. June 2003 igeneon presents cancer vaccine IGN101 Phase II data at the annual American Society of Clinical Oncology (ASCO) meeting Results show high immunogenicity despite concomitant chemotherapy Permits further testing in wide range of clinical settings 21. May 2003 4SC AG coses nine million Euro third round financing 9. May 2003 igeneon presents new scientific results at renowned international cancer congresses Presentations at ASCO and AACR Co-sponsor of iSBTc/Focis satellite symposium "Cellular Immunology and Immunotherapy of Cancer" 28. April 2003 4SC and ProQinase collaborate on the discovery of new protein kinase inhibitors for cancer treatment 3. April 2003 Epigenomics raises € 21 (US$ 22.5) million in a third round of financing 27. March 2003 New Chief Development Officer SWITCH Biotech AG appoints new Chief Development Officer for the future clinical development phases of trial substances 27. March 2003 AVONTEC GmbH recruits several internationally renowned scientists to form its Scientific Advisory Board 24. March 2003 SiREEN AG selects Evotec OAI as a partner to identify novel small molecule inhibitors against one of its targets 18. March 2003 Roche and Epigenomics sign broad cancer diagnostics alliance Companies to collaborate on diagnostic products for early cancer detection, classification, and treatment reponse 18. March 2003 Epigenomics licenses marker in blood from Johns Hopkins University that may indicate predesposition to colon cancer Potential To Develop First Test For Colon Cancer Predisposition From A Blood Sample 10. March 2003 First native DP IV-structure solved 27. February 2003 Further US-patent issued 25. February 2003 4SC and Boehringer Ingelheim sign research agreement for the identification of novel drug candidates against three targets 18. February 2003 igeneon and Immunicon form development alliance Cooperation between bio pharmaceutical and diagnostic companies on clinical studies to bring product development synergies and cost savings Potential for acceleration of time-to-market for cancer immunotherapies 17. February 2003 CARDION announces Licence of Genomics Enabler™ Technology to Pfizer Inc. 12. February 2003 Exclusive licence to Medication for the treatment of skin diseases 31. January 2003 4SC appoints vice president medicine to support the advancement of key drug candidates into clinical trials 30. January 2003 Danish LEO Pharma obtains license from SWITCH Biotech 27. January 2003 Epigenomics accesses additional DNA methylation technologies for early detection of tumors and expands its scientific advisory board 17. January 2003 DeveloGen and scientists from IPK Gatersleben publish data on key trigger for regenerating Insulin Producing Cells -- Study provides additional support in fight to treat diabetes -- 16. December 2002 4SC and academic research consortium receives EU grant to develop new drugs to treat S.Aureusinfections 12. December 2002 igeneon initiates Phase I clinical studies of two key cancer products and reaches major milestone FDA accepts IND for IGN301 allowing The Cleveland Clinic and igeneon to start joint Phase Ib study in U.S. IGN311 humanized antibody starts Phase I study at Augsburg Central Clinic igeneon now has three key products in clinical development 18. November 2002 probiodrug and Synt:em announce collaboration to develop compounds for certain drug targets for CNS 11. November 2002 4SC archieves first milestone in research collaboration with recordati to identifY novel drug candidates 5. November 2002 Epigenomics and Mayo Clinic collaborate on test for early detection of colorectal cancer 31. October 2002 igeneon strengthens project management organization 11. October 2002 SWITCH Biotech restructures its activities Focussing on the future 3. October 2002 Protarga to begin Pivotal Phase III study of new cancer drug In Patients with Metastatic Melanoma Clinical program to be presented at UBS Warburg conference in New York 2. October 2002 igeneon acquires cancer vaccine license - Further development of former Novartis product in Europe and the USA 25. September 2002 probiodrug grants license to Ferring and Ortho McNeil Pharmaceuticals 23. September 2002 CARDION closed € 11.5 million financing round 3. September 2002 DeveloGen appoints Dr. Klaus Brandau as Chairman of the Supervisory Board 31. July 2002 igeneon strengthens its management team 31. July 2002 Leading immunologist joins igeneon's Scientific Advisory Board - Ivan Roitt advising igeneon 29. July 2002 Protarga and ICOS begin research collaboration on new anti-cancer compounds Application of Targaceutical® Technology to novel anti-cancer agents 29. July 2002 Protarga and ICOS begin research collaboration on new anti-cancer compounds Application of Targaceutical® Technology to novel anti-cancer agents 11. July 2002 igeneon licenses humanized antibody in cancer from Protein Design Labs 10. July 2002 LEO Pharma and SWITCH Biotech Stocktaking after an exceptional year of co-operation with LEO Pharmaceutical Products Ltd. A/S 27. June 2002 Biopsytec closes second round financing over € 5 million. 20. June 2002 SWITCH Biotech is awarded the preliminary Work and Family Audit At the cutting edge of the Biotechnology sector 12. June 2002 Epigenomics' CEO Alex Olek receives first annual German StartUp award 10. June 2002 4SC decides to use IBM Linux Cluster technology, based on the eServer xSeries, for drug discovery 23. May 2002 Epigenomics CEO Alex Olek named one of the the world’s top young innovators by TECHNOLOGY REVIEW 16. May 2002 International prizes for research projects supported by SWITCH Biotech Double recognition for wound healing 7. May 2002 Protarga announces additions in oncology and clinical development Frank Bambarola appointed Vice President, Oncology and Timothy McKinlay appointed Senior Director, Clinical Operations 30. April 2002 SWITCH Biotech concludes third round of financing First investor from USA 26. April 2002 SWITCH Biotech strengthens its business development 25. April 2002 Epigenomics and Biopsytec cross-license revolutionary genetic based technologies 17. April 2002 DeveloGen names Dr. Günther Karmann as CEO Dr. Thomas Metz also appointed to newly created position of VP, Lead Discovery 3. April 2002 SWITCH Biotech offers a family-friendly working environment Competitive with 32 children? 27. March 2002 DeveloGen announces support of diabetes research by the European Comission 14. March 2002 SWITCH Biotech lays the foundations for co-operation with Japan Martinsried greets Japan with a "Konnichi wa" 6. March 2002 DeveloGen announces senior management appointments in business development and research 28. February 2002 SWITCH Biotech expands its vitiligo network - cooperation with the Charité in Berlin Goal: A Drug to Treat Vitiligo 25. February 2002 The Cleveland Clinic and igeneon to collaborate on new Cancer vaccine Research 29. January 2002 Cancer immunotherapy from igeneon: one step closer to marketability - the cancer vaccine IGN101 enters an extensive clinical trial in lung cancer patients 24. January 2002 SWITCH Biotech expands third round of financing Equity increased by Euro 3.6 million 17. January 2002 The most recent findings concerning wound healing SWITCH Biotech publishes articles in scientific journals 16. January 2002 Cancer immunotherapy from igeneon: one step ahead marketability - The cancer vaccine IGN101 enters the second clinical phase 14. January 2002 4SC and WILEX Sign cancer research collaboration to optimize second Generation UPA inhibitors